554 related articles for article (PubMed ID: 22251937)
1. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
Yachida S; Vakiani E; White CM; Zhong Y; Saunders T; Morgan R; de Wilde RF; Maitra A; Hicks J; Demarzo AM; Shi C; Sharma R; Laheru D; Edil BH; Wolfgang CL; Schulick RD; Hruban RH; Tang LH; Klimstra DS; Iacobuzio-Donahue CA
Am J Surg Pathol; 2012 Feb; 36(2):173-84. PubMed ID: 22251937
[TBL] [Abstract][Full Text] [Related]
2. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
3. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
4. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants.
Matsui K; Jin XM; Kitagawa M; Miwa A
Arch Pathol Lab Med; 1998 Nov; 122(11):1010-7. PubMed ID: 9822131
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
7. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma.
Kimura T; Miyamoto H; Fukuya A; Kitamura S; Okamoto K; Kimura M; Muguruma N; Ikemoto T; Shimada M; Yoneda A; Bando Y; Takishita M; Takayama T
Clin J Gastroenterol; 2016 Aug; 9(4):261-5. PubMed ID: 27262570
[TBL] [Abstract][Full Text] [Related]
9. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
[TBL] [Abstract][Full Text] [Related]
10. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract][Full Text] [Related]
12. Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor.
Takizawa N; Ohishi Y; Hirahashi M; Takahashi S; Nakamura K; Tanaka M; Oki E; Takayanagi R; Oda Y
Hum Pathol; 2015 Dec; 46(12):1890-900. PubMed ID: 26434631
[TBL] [Abstract][Full Text] [Related]
13. High-grade transformation of pancreatic neuroendocrine tumor associated with TP53 mutations: A diagnostic pitfall mimicking neuroendocrine carcinoma.
Tanaka M; Shinozaki-Ushiku A; Kunita A; Yasunaga Y; Akamatsu N; Hasegawa K; Ushiku T
Pathol Int; 2022 Aug; 72(8):411-418. PubMed ID: 35698921
[TBL] [Abstract][Full Text] [Related]
14. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
[TBL] [Abstract][Full Text] [Related]
15. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.
Basturk O; Tang L; Hruban RH; Adsay V; Yang Z; Krasinskas AM; Vakiani E; La Rosa S; Jang KT; Frankel WL; Liu X; Zhang L; Giordano TJ; Bellizzi AM; Chen JH; Shi C; Allen P; Reidy DL; Wolfgang CL; Saka B; Rezaee N; Deshpande V; Klimstra DS
Am J Surg Pathol; 2014 Apr; 38(4):437-47. PubMed ID: 24503751
[TBL] [Abstract][Full Text] [Related]
16. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
[TBL] [Abstract][Full Text] [Related]
17. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic features of primary renal neuroendocrine carcinoma].
Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609
[No Abstract] [Full Text] [Related]
19. Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
Bean GR; Najjar S; Shin SJ; Hosfield EM; Caswell-Jin JL; Urisman A; Jones KD; Chen YY; Krings G
Mod Pathol; 2022 Oct; 35(10):1349-1361. PubMed ID: 35590107
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
